|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| License and collaboration revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Change in fair value of derivative liabilities | |||||
| Change in fair value of non-controlling equity investments | |||||
| Change in fair value of contingent consideration liabilities | |||||
| Gain on sale of equity method investment | |||||
| Interest and other income (expense), net | |||||
| Total other income (expense) | |||||
| Net loss before income taxes | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Unrealized gain (loss) on marketable securities | |||||
| Comprehensive loss | |||||
| Net loss per common share, basic | |||||
| Net loss per common share, diluted | |||||
| Weighted - average common shares outstanding, basic | |||||
| Weighted - average common shares outstanding, diluted |
Loading...
